awmsg logo



dolutegravir (Tivicay®)


Reference No. 3373

Publication date:
19/10/2017


Appraisal information

dolutegravir (Tivicay®) 10 mg, 25mg tablet


Company: ViiV Healthcare UK Ltd
BNF category: Infections
NMG meeting date: 06/09/2017
AWMSG meeting date: 11/10/2017
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2017
Ministerial ratification: 18/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Dolutegravir (Tivicay®) is recommended as an option for use within NHS Wales in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download